Try our Advanced Search for more refined results
Life Sciences - March, 2013
290 articles
- FDA Greenlights J&J's Controversial Diabetes Drug
- Alphatec Shakes Securities Suit Over French Firm Buy
- 6 Health Policies A Gridlocked Congress Can Get Behind
- Pfizer Can't Shake Securities Action Over Celebrex Risks
- Medtronic Asks High Court To Weigh IP Case Burden Of Proof
- Ropes & Gray Aids TPG In $173M Chinese Pharma Buyout
- US Wins $10M Judgment For Illegal Primrose Oil Imports
- DePuy Hip Implant Patient Tells Jury Of Pain After Surgeries
- Generic Darvocet Cos.' Mass Action Jurisdiction Claim Denied
- Allergan Drops Patent, Ad Claims Over Eyelash Drug Latisse
- Reading The Labels Of Par And Harkonen
- Product Makers Stand To Profit From Pa. Tort Law Change
- Texas Attorney Stole Pfizer Settlement, Ex-Clients Say
- Alexion Gets FDA Warning Over Contamination At RI Plant
- Husband Recounts Constant Pain At DePuy Hip Implant Trial
- Covidien Nets $177M From J&J Unit In Scalpel Patent Suit
- Fed. Circ. Rejects Bid To Add Inventors To MGH Gene Patents
- Medifast Freed From Investors' Securities Fraud Suit
- Quest Can't Duck Claims That It Pushed Out Older Sales Reps
- New MS Drug Approved By FDA Despite Teva's Opposition
- Pharmacies Lose Suit Calling CMS Rule Anti-Competitive
- Medicare Asleep On $70M Equipment Overpayments, OIG Says
- Wilson Sonsini Adds 5 Sidley Austin IP Litigation Attys
- W.Va. AG's Pill Mill Suit Kicked Back to State Court
- Gilead Poached Worker To Launch Rival Drug, Vertex Says
- Whisteblower Says Biotech Co. Used Family For US Contracts
- Deals Rumor Mill: Bain Capital, Dell, BayernLB
- 5 Things To Know About Oral Argument In FTC V. Actavis
- Litigation Support At A Crossroads
- BioMed Realty Strikes $640M Merger Deal With Wexford
- Fla. Judge Nixes Punitive Damages In Novartis Zometa Row
- Illumina Can't Revive DNA-Sequencing Patent Claims
- The Business End Of Supreme Court's Current Term
- Insurers Object To $4.8M Ferring, Aventis Antitrust Deal
- Pfizer Sues To Block Lupin's Generic Bladder-Control Drug
- Pfizer Settles Suit Over Rimadyl Dog Death
- Merck Atty's Letter Ruled Harmless In Whistleblower's Suit
- Walgreen, Insurer End Avastin Eye Injury Coverage Suit
- Fired Exec Slaps NY Hospital With $30M Defamation Suit
- Doc Gets 6 Years, To Pay $4.5M For Fen-Phen Settlement Fraud
- Doc-Owned Device Cos. Carry Fraud Risk, Inspector Warns
- Human Genome, GSK Dodge Lupus-Drug Suicide Suit
- Device Tax Repeal Faces Tough Slog Despite Senate Vote
- The 5 Litigators Sure To Drive Judges Mad
- Grand Jury Probe Sought In NECC Meningitis Outbreak
- Joining US, EU Probes Diabetes Drugs' Safety
- J&J Recalls 1.9M Blood Glucose Meters
- Life Sciences Rising Star: Gibson Dunn's Steven Tave
- DePuy Worker Warned Of Hip Design Problems, Jury Hears
- Actos 'Most Substantial' Factor In Man's Cancer, Doc Testifies
- Headset Maker Files Appeal Over €1B Blocked Sonova Sale
- Pfizer Wins Promotion Contract Row In Pa. Appeals Court
- What Food Cos. Can Learn From Horses And Peanuts
- 5 Tips For Making It Rain
- Chinese Vitamin Cos. To Pay $23M To Settle Price-Fixing Plot
- WR Grace Sues Teledyne Over Chemical-Process Patent
- Valeant's $344M Obagi Buy Rips Off Investors, Suit Says
- Okla. Device Ruling Puts Other Products In Crosshairs
- Latest FDA User Fee Bill Unlikely To Include Major Reforms
- Cooley Moves To Bigger Offices In Seattle
- Plaintiffs Attys Say Sky's Not Falling After CAFA Ruling
- Argon Pays $363M For Angiotech's Device Business
- NJ Panel Refuses To Revive Fosamax 'Jaw Death' Suit
- Lasik For Farsightedness Not Illegal Experiment: 9th Circ.
- Judge Stands By Decision Preempting DC Defamation Law
- High Court Split On Antitrust Test For Pay-For-Delay Deals
- Rising Star: Kirkland's Mike Shumsky
- FDA Challenges Execution Drug Ban In DC Circ.
- DePuy Hip Implants Appeared To Be Safe, Surgeon Testifies
- Watson Can't Skirt Shire's Colitis Drug Patent Suit
- Actavis, AstraZeneca Settle Crestor Generic Suit
- Sanofi Urges DC Circ. To Force Subpoena In Antitrust Suit
- FDA's New Device Review Policy Hits Some Speed Bumps
- Senate Signals Wide Support For $29B Device Tax Repeal
- Doc Testifies DePuy Hip Implant Debris Caused Bone Damage
- House Bill Aims To Limit Oxycodone Prescriptions
- Pfizer Settles With EPA On $205M NJ Superfund Cleanup
- Supreme Court Tames Class Action Frankenstein's Monster
- Mako Sues Rival Device Co. Over Robotic Surgery Patents
- Doc Testimony Over Discontinuing NuvaRing Axed From MDL
- MLB Says Clinic Hurt League By Hawking Drugs To Players
- Rising Star: Axinn Veltrop & Harkrider's Chad Landmon
- DC Circ. Defers To FDA In Stem Cell Device Marketing Row
- FDA Wants Tougher Scrutiny Of Emergency Defibrillators
- Nordion Settles Dr. Reddy's $80M Negligent Testing Suit
- Deals Rumor Mill: Life Technologies, PepsiCo, CVC Capital
- Life Sciences Cos. Faced 65% More Securities Suits In 2012
- Ky. Disbars Stanley Chesley Over $200M Fen-Phen Settlement
- Bayer Contests Consolidation Of Mirena IUD Defect Cases
- J&J Misled On Viactiv's Vitamin D Content, Suit Says
- 11th Circ. AndroGel Decision Bolsters FTC Pay-For-Delay Case
- AstraZeneca Pushes DC Circ. To Stretch Seroquel Exclusivity
- Va. Gov. Signs Nation's 1st Biosimilar Substitution Law
- Illumina Beats Life Tech DNA Patent Infringement Claims
- DC Circ. Blasts DEA Shipping Ban On Walgreen Facility
- AstraZeneca Places $420M Bet On Mass. Biotech Startup
- Delaware Rethinks Reverse Triangular Mergers
- In Re Hubbell Puts Inventors At A Disadvantage
- GOP Wins Promise Of Light Medical App Regulation From FDA
- 7 Reasons To Do Pro Bono Work
- Sanofi Investors Win Class Cert. In Obesity Drug Suit
- Stryker Can't Shake Hip Device Class Action
- Discovery Barred In Patent Re-Exams, Fed. Circ. Rules
- IP Atty Takes On Wall Street Over Herbalife 'Pyramid Scheme'
- Pay-For-Delay To Test High Court's Pro-Settlement Stance
- Pricey Pfizer Drug Spurs Call For NIH Collaboration Probe
- Bills Would Tighten Hydrocodone Dispensing Restrictions
- FDA Warnings Over Eye Infections Spark Partial Avastin Recall
- Ferring's Trade Secrets Claims Cut In $165M Patent Deal Row
- Valeant Inks $344M Deal For Skin Care Co. Obagi
- AstraZeneca Targets Actavis In Latest Nexium IP Suit
- Keep Watch Of French Authority's Pharma Sector Inquiry
- Avoid The Top 10 Pitfalls In A Jury Charge Conference
- Bayer Pays $24M To Settle Yaz, Yasmin Gallbladder Cases
- High Court's CAFA Ruling Carries Dangers For Defendants
- Class Action Lawyers React To Supreme Court's CAFA Ruling
- High Court Urged To Bar Fees For Untimely Vaccine Claims
- Jones Day Lures Atlanta FCA Experts From Nelson Mullins
- Bayer, Merial Fetch Win In Flea Medication MDL
- FDA Selects Interim Director For Office Of Generic Drugs
- McKesson Wages Suit Settlement May Harm Class, Judge Says
- Stryker Exec Who Jumped Ship Must Hand Over Trade Secrets
- Supreme Court Weighs Future Of Generic-Drug Defect Suits
- Walgreen Inks 10-Year Partnership Deal With Amerisource
- Lawmakers Push FDA To Finalize Mobile Health App Rules
- Affymax Mulls Bankruptcy After Anemia Drug Recall
- Deals Rumor Mill: Dell, Gazprom, Deutsche Telekom
- What You Should Know About PPACA Reporting Rules
- Justices Restore Class Action Fairness Act's Removal Power
- And Now A Word From The Panel ...
- FDA Approval Preempts DePuy Knee Device Suit, Judge Says
- Bingham Snags Transaction Experts From Foley, Dinsmore
- Cephalon Hit With FCA Suit Over Off-Label Marketing
- House Panel Readies Attack On FDA App Oversight
- Compounder Recalls All Products After Mold Found
- FDA Recommends Postponing Abbott MitraClip Approval
- WilmerHale Lands Ex-Ropes & Gray FDA Expert
- Justices Asked To Nix Fed. Circ. Claims Construction Rule
- FDA Told To Improve Complaints Tracking For Supplements
- Mistrial Declared In Merck's 1st Fosamax Femur Trial
- GSK, L'Oreal, Others Fined €39M Over Pricing Scheme
- Dendreon Pays $40M Over Claims It Inflated Provenge Demand
- Current Trends In FDA's Good Manufacturing Enforcement
- What Litigators Must Know About Va.'s 'Rocket Docket'
- UK Court Revokes 2 Novartis Patents In Bone Drug Row
- Historic Insider Trading Deal A Warning To Hedge Funds
- MDL Judge Limits Medical Fee Claims In 46 Novartis Suits
- For Biosimilar Developers, Honeymoon May Be Over
- Plaintiff Wants J&J Unit TCPA Junk Fax Suit Reopened
- HHS Updates State Medicaid FCA Compliance Rules
- West-Ward Lobs $175M False Ad Suit At Generic-Drug Rivals
- Ropes & Gray Skirts IP Malpractice Suit After Gunn Ruling
- Abbott Escapes Ensure Drinker's False Ads Suit
- Spectrum Pharmaceuticals Hit With Shareholder Class Action
- SAC Unit Will Pay $600M To Settle Insider Trading Claims
- Reading Tea Leaves After Amgen
- Syntrix Wins $96M Verdict Against Illumina In DNA Patent Suit
- FDA Says It Caved To Politics In Clearing ReGen Implant
- C.R. Bard Ducks FCA Suit Over Catheter Kickbacks
- Expert Networker Gets 1 Year For Passing Abaxis Tips
- FDA Warns Fresenius Medical Over Dialysis Device
- Teva To Pay $2M To Resolve Toxic Discharge Suit
- FDA Generic-Drug Leader Steps Down Amid Agency Changes
- Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal
- Jury Finds Chinese Vitamin C Makers Fixed Prices
- FDA Will Probe Diabetes Drug Safety Risk Report
- High Court Urged By Doctors To Uphold Myriad Gene Patents
- Abbott Accuses Ex-VP, Boston Scientific Of Raiding Sales Staff
- How FDA Differs From CMS In Clinical Lab Test Oversight
- FDA's Risk-Benefit Plan May Drive More Drug Approvals
- Dr. Reddy's Still Can't Duck Suit Over Generic Angiomax
- Forest Labs Can't Escape Class Action Over Junk Faxes
- DLA Piper Snags Global IP Pro From Squire Sanders
- Icahn, Banks Propping Up Herbalife Scheme, Short-Seller Says
- Endo Medical Mesh Suit Booted Back To Calif. Court
- Insurer Disputes Duty To Defend In Drug Co.'s Pill Mill Suit
- Fla. House Panel Approves Bill To Beef Up State FCA
- Mylan Settles Fortamet Patent Suit With Shionogi, Andrx
- FDA Can Regulate Stem Cell Treatment As Drug, DC Circ. Hears
- 6th Circ. Says Pliva Failure-To-Warn Claims Not Preempted
- IMS Health Inks $100M Deal For Marketing Software Firm
- Foley & Lardner Accused Of Botching Medical Patent Suits
- The Outer Limits Of Expert Testimony Gatekeeping
- Class Cert. Bid Flawed In Transitions Antitrust Row: Judge
- FTC's Take On Drug Sales To Rivals May Cost Pharma
- Stryker Warned By FDA For Marketing Of Recalled Device
- Medtronic Fights $10M Catheter IP Verdict In Fed. Circ.
- Merck's Fosamax Caused Femur Fractures, Jury Hears
- Carolina Casualty Can't Dodge FCA Coverage
- FDA Promoted Illegal Compounding, KV Tells DC Circ.
- Waiora Pays $12M To Settle Suit Over Anti-Aging Supplement
- Polsinelli Nabs Health Pro With FCPA Chops From Mintz Levin
- Remember To Pay Attention To Antitrust Standing Issues
- Kline & Specter Sues 2 Firms Over GSK Dental Cream Deals
- Pfizer Antibiotic Linked To Deadly Heart Disorder, FDA Warns
- House Bill Would Authorize Medicare Drug Price Negotiations
- DC Circ. Rules FDA Properly Approved Skin Oil Generics
- A Bitter Loss For POM Signals More FTC Scrutiny
- Deals Rumor Mill: KKR, Carlyle, Lenovo
- Hedge Fund Creator Decries SEC's Attempt At D&O Ban
- Pfizer Deal Marks A Missed Chance For Branded-Drug Cos.
- 'Knockoff' Blood Clot Product Still On Market: Supplement Co.
- CORRECTED: Insurer Says Cracked Security System Led To $80M Lilly Theft
- Blaming Vitamin C Price Hike On SARS Absurd, Jury Hears
- State AGs Push For Abuse-Resistant Generic Painkillers
- 6th Circ. Says $3B Dow Deal Requires Authorization Of Credits
- Myriad Defends Cancer Gene Patents To Supreme Court
- High Court Asked To Hear Generic Reglan Design Defect Suit
- Expert Networker's Insider Trading Warrants Prison, US Says
- J&J's Win Upheld In Antibody Patent Fight Against Abbott
- Mylan Says Teva's MS Drug IP Suit Doomed By Safe Harbor
- Merck, BMS Target Hetero Over Generic HIV Drug Sustiva
- Getting The Wrinkles Out Of Anti-Aging Products
- Corning To Pay $6M To Settle GSA False Claims Suit
- Glenmark Asks Fed. Circ. To Nix Patent In $16M Abbott Win
- Warner 'Confused' About Doryx Contracts, Retailers Say
- FDA's New Safety Reports Raise Tort Risks For Device Cos.
- Sanofi Facing DOJ Investigation Over Plavix Disclosures
- Law360 Names Top Attorneys Under 40
- Lupin Can't Escape Gilead's Ranexa Patent Suit
- Judge Sides With Allergan On Eyelash-Growth Patent Claim
- AstraZeneca Affiliate Wants Ch. 11 Nixed Due To Cost
- Fujifilm, GE Near Escape From Tumor Monitoring Patent Suit
- DePuy Hit With $8.3M Verdict Over Metal Hip Implant
- FDA Urges More Accuracy On 'Latex Free' Med Supply Labels
- Wash. High Court Won't Let Insurers Recoup Defense Costs
- Warner Chilcott Misbranded Drugs, FCA Kickback Suit Says
- Icahn Raises Herbalife Stake To 15.5% Amid Ackman Fight
- Takeaways From FDA's 1st Waiver Decision
- FDA Unveils Draft Plan For New Benefit-Risk Framework
- Amazon Accused Of 'Bait-And-Switch' In Supplement Ads
- Insurers Sue To Shirk Defense Of J&J Counterfeiting Suit
- Pa. Appeals Court Tosses Paxil Birth Defect Suit
- Whistleblower Can Pursue FCA Suit Over Vascular Treatments
- Off-Label Drug Coverage Bill Clears NJ Assembly Panel
- EU Food Business Operators Still Have A Lot To Chew Over
- Immucor Puts Up $4M To Settle Price-Fixing Coverup Claims
- Affymax Sued Over $500M Stock Drop Linked To Recall
- Teva's Defective IUD Caused Injuries, $15M Suit Says
- Ranbaxy Ducks Wider Recall In Glass Particles Class Action
- Shire Wins Dismissal Of Adderall Antitrust Suit
- $85M Default Risk Keeps K-V Pharma Ch. 11 Plan On Schedule
- 5th Circ. Upholds Block On Blood Clot Supplement 'Knockoff'
- Ferring, Aventis To Pay $4.8M To End Drug Antitrust Suit
- Royalty Keeps Pushing $6.6B Buyout Despite Elan's Refusal
- More FDA Detention Slips For Food Cos.
- A Look At The Health Care M&A Horizon
- AstraZeneca Escapes $100M AWP Suit Over Nexium
- FDA Issues Guidelines For Back-And-Forth In Device Reviews
- FDA Says Hospira Plant Continues To Have Quality Issues
- FDA Again Delays Expanded Use Of Blood Thinner Xarelto
- Pfizer Beats Medicare Fraud Suit Over Pain Patch Marketing
- Budget Bill Includes Fix For FDA's Medical Device User Fees
- GSK, Thalidomide Plaintiffs Spar Over Pa., Federal Jurisdiction
- 9th Circ. Upholds Ex-InterMune CEO's Fraud Conviction
- Express Scripts Says Class Action's Recall Bid Hits FDA Turf
- Impax Still Needs To Fix Production Plant Issues, FDA Says
- Pfizer Targets Generic Celebrex After Extending Patent
- Par To Pay $45M For Off-Label Marketing Of AIDS Drug
- Fen-Phen Claimant Wrongly Denied Benefits, 3rd Circ. Told
- A New Trend In Health Care Fraud Settlements
- MIT Loses Ownership Bid In IP Row Over Anti-Cancer Device
- Pfizer Ducks Class Cert. In ERISA Suit Over Wyeth Merger
- House GOP Fears ACA's Device Tax Could Hit Smartphones
- Novartis Hit With $250K Verdict In Zometa Jaw Injury Suit
- Baxter Urges Fed. Circ. Not To Reopen Fresenius Battle
- Drug Biz Wants Strong IP Measures In Pacific Trade Pact
- Healthpoint, DFB Settle With Pa. In Skin Ointment FCA Row
- Chinese Vitamin C Makers Fabricated Export Docs, Jury Told
- XL, Ace Off The Hook For $850M Seroquel Defense Costs
- Novartis Gets NJ Damages Applied To Fla. Bone Drug Suit
- Novo Nordisk Asks Fed. Circ. To Save Prandin Patent
- Zimmer, Marketing Co. Win New Trial In Knee Injury Case
- Roche Appeals Recusal Ruling In NJ Accutane Suits
- Elan Sweetens Deal To Counter $6.6B Takeover Bid
- Promega Seeks New Trial In Gene-Testing Patent Row
- 1st-To-File System Isn't New To Drug Companies
- The Pressure Is On For 340B Entities
- Sun Pharma Demands Generic Cancer Drug Market Exclusivity
- Depomed Targets Generics Maker Over Diabetes Drug IP
- Chancellor Strine's View On Disclosures Evolving, Attys Say
- Pill Maker Settles $100M Insurance Row Over Thailand Flood
- Angina Drug's Minty Taste, Smell Can't Be Trademarked: TTAB
- Merck To Kick Off 2nd Round Of Fosamax Suits In NJ
- K-V Creditors Ask Judge To Delay Ch. 11 Plan Hearing
- Momenta, Sandoz Ask Justices To Clarify Safe Harbor Rule
- Lance Armstrong Endorsements Founded On Lies, Class Says
- FDA's Facebook Slap Gives Drug Industry Little To Like
- Roche Inches Closer To Escaping Accutane MDL
- Supreme Court Warned Of Risks Of Banning Pay-For-Delay